HCPCS Code G0476

Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test
Code effective Jul 09, 2015

HCPCS Section
Procedures/Professional Services (Temporary Codes)

G0476 is a valid 2026 HCPCS code meaning Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test or (Hpv combo assay ca screen) for short. HCPCS G0476 has been effective since 07/09/2015 and applies to Diagnostic laboratory.

HCPCS Code Details - G0476

HCPCS Level II Code
Section G - Procedures/Professional Services (Temporary Codes)
HCPCS Code G0476
Description

Long description:
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test

Short description:
Hpv combo assay ca screen

HCPCS Pricing indicator 13 - Clinical Lab Fee Schedule - Price established by carriers (e.g., not otherwise classified, individual determination, carrier discretion)
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Coverage code C - Carrier judgment
BETOS2 code T2D - Other tests - other
HCPCS Action code N - No maintenance for this code
Type of service 5 - Diagnostic laboratory
Effective date Effective Jul 09, 2015
Date added Added Jul 09, 2015

See also

  • HCPCS G0475 · Hiv antigen/antibody, combination assay, screening

  • HCPCS G0567 · Infectious agent detection by nucleic acid (dna or rna); hepatitis c, screening, amplified probe technique

  • HCPCS U0003 · Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r

  • HCPCS U0005 · Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2

  • HCPCS G0477 · Drug test(s), presumptive, any number of drug classes; any number of devices or procedures, (e.g., immunoassay) capable of being read by direct optical observation only (e.g., dipsticks, cups, cards, cartridges), includes sample validation when performed, per date of service

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.